Back to Journals » International Journal of Nanomedicine » Volume 10 » Special Issue on diverse applications in Nano-Theranostics

Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery

Authors Joo JY, Park GY, An SSA

Received 11 May 2015

Accepted for publication 20 July 2015

Published 1 September 2015 Volume 2015:10(Special Issue on diverse applications in Nano-Theranostics) Pages 101—111

DOI https://doi.org/10.2147/IJN.S88381

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Zhengjian Lv

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas J Webster

Supplementary video presented by Joo et al.

Views: 277

Jae Yeon Joo, GilYong Park, SeongSoo A An

Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si, Republic of Korea

Abstract: In the development of effective drug delivery carriers, many researchers have focused on the usage of nontoxic and biocompatible materials and surface modification with targeting molecules for tumor-specific drug delivery. Fibrinogen (Fbg), an abundant glycoprotein in plasma, could be a potential candidate for developing drug carriers because of its biocompatibility and tumor-targeting property via arginine–glycine–aspartate (RGD) peptide sequences. Doxorubicin (DOX), a chemotherapeutic agent, was covalently conjugated to Fbg, and the microspheres were prepared. Acid-labile and non-cleavable linkers were used for the conjugation of DOX to Fbg, resulting in an acid-triggered drug release under a mild acidic condition and a slow-controlled drug release, respectively. In vitro cytotoxicity tests confirmed low cytotoxicity in normal cells and high antitumor effect toward cancer cells. In addition, it was discovered that a longer linker could make the binding of cells to Fbg drug carriers easier. Therefore, DOX–linker–Fbg microspheres could be a suitable drug carrier for safer and effective drug delivery.

Keywords: biocompatibility, anti-cancer drug, micro-structure, cytotoxicity, bio-conjugation, tumor targeting

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]